Case number 1:18-cv-01586
Teva Pharmaceuticals International GmbH et al v. Fresenius Kabi USA, LLC et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jul 6, 2020 | N/A | Terminated Case (0) Docket Text: CASE CLOSED per Final Judgment Order in Lead Case. CA. NO. 17-1154-CFC. (fms) |
| Jan 7, 2019 | N/A | Remark (0) Docket Text: The Scheduling Conference set for 1/9/2019 at 03:30 PM is cancelled per D.I. [16]. (nmf) |
| Jan 7, 2019 | N/A | Create Case Association (0) Docket Text: Case associated with lead case: Create association to 1:17-cv-01154-CFC. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE 17-1154-CFC ONLY. (nmf) |
| Jan 7, 2019 | 15 | Stipulation (4) Docket Text: STIPULATION and Proposed Order to Consolidate by Cephalon, Inc., Eagle Pharmaceuticals, Inc.. (Hoeschen, Nathan) |
| Jan 7, 2019 | 16 | SO ORDERED (4) Docket Text: SO ORDERED, re (15 in 1:18-cv-01586-CFC, 225 in 1:17-cv-01154-CFC) STIPULATION AND ORDER TO CONSOLIDATE. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 17-1154-CFC ONLY. Signed by Judge Colm F. Connolly on 1/7/2019. Associated Cases: 1:17-cv-01154-CFC, 1:18-cv-01586-CFC(nmf) |
| Dec 10, 2018 | 14 | Order Setting Scheduling Conference (1) Docket Text: Order Setting Scheduling Conference: A Scheduling Conference is set for 1/9/2019 at 03:30 PM in Chambers before Judge Colm F. Connolly. Signed by Judge Colm F. Connolly on 12/10/2018. (nmf) |
| Nov 27, 2018 | 13 | Answer to Counterclaim (8) Docket Text: ANSWER to [9] Answer to Complaint, Counterclaim (Answer to Fresinus Kabi USA, LLC's Counterclaims) by Cephalon, Inc., Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH.(Hoeschen, Nathan) |
| Nov 9, 2018 | 11 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint, by Mylan Laboratories Ltd..(Lennon, James) |
| Nov 9, 2018 | 12 | Disclosure Statement (3) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Mylan Inc., Corporate Parent Mylan N.V. for Mylan Laboratories Ltd. filed by Mylan Laboratories Ltd.. (Lennon, James) |
| Nov 6, 2018 | 9 | Answer to Complaint (27) Docket Text: ANSWER to [1] Complaint, , COUNTERCLAIM against Cephalon, Inc., Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH by Fresenius Kabi USA, LLC.(Farnan, Brian) |
| Nov 6, 2018 | 10 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Fresenius Kabi Pharmaceuticals Holding, LLC, Other Affiliate Fresenius Kabi AG, Other Affiliate Fresenius SE & Co. KGaA for Fresenius Kabi USA, LLC filed by Fresenius Kabi USA, LLC. (Farnan, Brian) |
| Nov 5, 2018 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [8] Stipulation filed by Cephalon, Inc., Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc., Set/Reset Answer Deadlines: Mylan Laboratories Ltd. answer due 11/13/2018. Signed by Judge Colm F. Connolly on 11/5/2018. (fms) |
| Nov 2, 2018 | 8 | Stipulation (2) Docket Text: STIPULATION (and proposed order) concerning service of process and Answer to Complaint - Answer Due November 13, 2018 by Cephalon, Inc., Eagle Pharmaceuticals, Inc., Teva Pharmaceuticals International GmbH. (Hoeschen, Nathan) |
| Oct 17, 2018 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) |
| Oct 16, 2018 | N/A | Summons Issued (0) Docket Text: Summons Issued with Magistrate Consent Notice attached as to Fresenius Kabi USA, LLC on 10/16/2018; Mylan Laboratories Ltd. on 10/16/2018. Requesting party or attorney should pick up issued summons at the Help Desk, Room 4209, or call 302-573-6170 and ask the Clerk to mail the summons to them. (nmg) |
| Oct 15, 2018 | 1 | Exhibit A (12) |
| Oct 15, 2018 | 1 | Exhibit B (13) |
| Oct 15, 2018 | 1 | Civil Cover Sheet (1) |
| Oct 15, 2018 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmg) |
| Oct 15, 2018 | 3 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: See Attached. Date of Expiration of Patent: See Attached. (nmg) |
| Oct 15, 2018 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 10,052,385 B2; US 10,010,533 B2. (nmg) |
| Oct 15, 2018 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Teva Pharmaceutical Industries Ltd. for Teva Pharmaceuticals International GmbH filed by Teva Pharmaceuticals International GmbH. (nmg) |
| Oct 15, 2018 | 6 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Teva Pharmaceutical Industries Ltd. for Cephalon, Inc. filed by Cephalon, Inc.. (nmg) |
| Oct 15, 2018 | 7 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Eagle Pharmaceuticals, Inc.. (nmg) |
| Oct 15, 2018 | 1 | Complaint* (1) |
